Product overview

Name LIH383
Biological description

Novel, potent and highly selective atypical chemokine receptor ACKR3 (CXCR7) agonist. Competes directly with CXCL12-AF647 for ACKR3 binding at low nanomolar concentrations and is more potent in inducing beta-arrestin recruitment to ACKR3 (EC50 = 0.61 nM) than the CXCL12 and CXCL11 chemokine ligands (EC50 = 1.2 and 2.2 nM respectively). Restrains the negative regulatory function of ACKR3 on opioid peptides to potentiate their activity in rat brain.

Purity >95%

Potent and selective ACKR3 (CXCR7) agonist. Potentiates opioid peptide activity.

Write Your Own Review
You're reviewing:LIH383
Rate this item:

Solubility & Handling

Storage instructions -20°C
Solubility overview

Soluble in aqueous buffer

Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use



More Info


More Info

Chemical Data

Purity >95%
Molecular Weight 997.23
Molecular Formula C45H72N16O8S
Sequence (one letter) FGGFMRRK-NH2
Sequence (three letter) H-Phe-Gly-Gly-Phe-Met-Arg-Arg-Lys-NH2
Modifications Amide at C terminal lysine

References for LIH383

References are publications that support the biological activity of the product
  • The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides

    Meyrath M et al (2020) Nat Commun 11(1) : 3033

1 Item